TVTX — Travere Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $625.78m
- $562.43m
- $145.24m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -146 | -169 | -180 | -278 | -111 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 65.2 | 127 | 58.7 | 58.2 | -182 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 2.63 | -25.2 | 80 | 0.904 | -25.5 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -58.2 | -42.7 | -14.8 | -186 | -280 |
Capital Expenditures | -15.6 | -24.6 | -24.2 | -28.6 | -42.3 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 35.4 | -36.8 | -113 | -4 | 98 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 19.9 | -61.3 | -138 | -32.6 | 55.8 |
Financing Cash Flow Items | -3.69 | -7.7 | -6.09 | -11.5 | -0.316 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -2.08 | 128 | 232 | 118 | 219 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -40.4 | 22.3 | 81 | -104 | -3.51 |